OI-83463 / Onco-Innovations - LARVOL DELTA

Onco-Innovations Limited…is pleased to announce that it is initiating a pilot project with Kuano Ltd. (Kuano) to accelerate development of Onco’s PNKP Inhibitor Technology (also known as A83B4C63) (ACCESS Newswire) - "This collaboration marks an important step in Onco's mission to harness advanced technologies, in this case computational platforms, to unlock novel cancer treatment mechanisms and drive faster, more precise therapeutic innovation....Kuano's advanced quantum molecular modelling is expected to provide a detailed characterization of how A83B4C63 interacts with PNKP, including binding poses, conformational changes, and the mechanism of inhibition underlying Onco's PNKP Inhibitor Technology....The pilot will run through the fourth quarter of 2025 and is expected to deliver validated platform outputs, structural binding models, and mechanistic hypotheses."

Licensing / partnership • Oncology

Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials (ACCESSWIRE) - "Onco-Innovations Limited...is pleased to announce that it has entered into an agreement with Nucro-Technics Inc. ('Nucro-Technics'), dated July 3, 2025, pursuant to which Nucro-Technics is to conduct a broad range of preclinical studies in support of the Company's lead drug candidate....The contract with Nucro-Technics covers the full scope of IND-enabling work for Onco's lead program, NP/A83 (OI-83463), a polymer-encapsulated PNKP inhibitor being developed for patients with advanced-stage, PTEN- or SHP-1-deficient cancers....This agreement marks a significant step in Onco's regulatory preparation efforts, as the studies conducted are aimed at generating both pharmacokinetic and safety data essential for moving the Technology into clinical testing."

Licensing / partnership • Oncology

Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma (ACCESSWIRE) - "Onco-Innovations Limited...is pleased to announce that Dalton Pharma Services ('Dalton') has commenced activities to manufacture material for preclinical testing of the Company's exclusively-licensed nanoparticle-formulated Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor technology....The current phase of work includes process optimization and scale-up manufacturing aimed at producing 50 grams of Onco's proprietary PNKP inhibitor, known as A83B4C63. This material will be used in preclinical studies, including in-vitro and in-vivo testing, and is intended to support regulatory preparations for an Investigational New Drug (IND) submission in the United States, which the Company plans on making this year."

Commercial • IND • Solid Tumor

Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology (ACCESSWIRE) - "Onco-Innovations Limited...is pleased to announce that it has entered into an agreement with Dalton Pharma Services ('Dalton') dated April 8, 2025, for the custom synthesis of a heavy labelled isotope of its exclusively-licensed Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor (the 'Technology'), based on a nanoparticle formulation of second-generation PNKP inhibitor, which when used as a monotherapeutic, was shown to increase the survival time of PTEN-deficient colorectal cancer tumor-bearing mice in a June 2021 study....This agreement with Dalton marks a critical step toward advancing IND-enabling animal model research....The Study referenced above involved using a PTEN-deficient colorectal cancer (CRC) xenograft mouse model, intravenous administration of the nanoparticle-encapsulated A83B4C63 (the PNKP Inhibitor compound), which resulted in a noticeable increase in median survival."

Licensing / partnership • Colorectal Cancer

Onco-Innovations’ Licensed Technology Shown in Study to Successfully Prevent Regeneration of Cancer Cells (ACCESSWIRE) - "Onco-Innovations Limited...is pleased to provide information on its exclusively-licensed technology, a new class of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors (the 'Technology'), which was shown in a study to successfully prevent the regeneration of cancer cells, by disrupting DNA repair processes, making cancer cells more vulnerable to radiation therapy and thereby improving patient outcomes. Onco-Innovations' new generation of PNKP inhibitors targets a key enzyme involved in cancer cell DNA repair. By inhibiting PNKP, these compounds can prevent cancer cells from repairing damage caused by radiation therapy, significantly boosting the therapy's effectiveness."

New molecule • Oncology